This is a Validated Antibody Database (VAD) review about mouse Gm10499, based on 84 published articles (read how Labome selects the articles), using Gm10499 antibody in all methods. It is aimed to help Labome visitors find the most suited Gm10499 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
Gm10499 synonym: MumuTL

BioLegend
mouse monoclonal (28-8-6)
  • flow cytometry; mouse; 1:100; loading ...
BioLegend Gm10499 antibody (Biolegend, 114605) was used in flow cytometry on mouse samples at 1:100. elife (2022) ncbi
mouse monoclonal (AF6-88.5)
  • flow cytometry; mouse; loading ...
BioLegend Gm10499 antibody (Biolegend, 116517) was used in flow cytometry on mouse samples . Front Immunol (2022) ncbi
mouse monoclonal (28-8-6)
  • flow cytometry; mouse; loading ...; fig 6e
BioLegend Gm10499 antibody (Biolegend, 114613) was used in flow cytometry on mouse samples (fig 6e). iScience (2022) ncbi
mouse monoclonal (AF6-88.5)
  • flow cytometry; mouse; loading ...; fig s6b
BioLegend Gm10499 antibody (BioLegend, AF6-88.5) was used in flow cytometry on mouse samples (fig s6b). Proc Natl Acad Sci U S A (2022) ncbi
mouse monoclonal (KH95)
  • flow cytometry; mouse; fig 3a, 3b, 4b
BioLegend Gm10499 antibody (BioLegend, KH95) was used in flow cytometry on mouse samples (fig 3a, 3b, 4b). J Immunother Cancer (2022) ncbi
mouse monoclonal (AF6-88.5)
  • flow cytometry; mouse; fig 3a, 3b, 4b
BioLegend Gm10499 antibody (BioLegend, AF6-88.5) was used in flow cytometry on mouse samples (fig 3a, 3b, 4b). J Immunother Cancer (2022) ncbi
mouse monoclonal (34-1-2S)
  • flow cytometry; mouse; 1:100; fig s4b
BioLegend Gm10499 antibody (BioLegend, 114706) was used in flow cytometry on mouse samples at 1:100 (fig s4b). Cell Rep (2022) ncbi
mouse monoclonal (34-1-2S)
  • flow cytometry; mouse; 1:50; loading ...; fig 5d, s6s
BioLegend Gm10499 antibody (Biolegend, 114713) was used in flow cytometry on mouse samples at 1:50 (fig 5d, s6s). Nat Commun (2022) ncbi
mouse monoclonal (AF6-88.5)
  • immunohistochemistry - paraffin section; mouse; 1:100; fig s6l
BioLegend Gm10499 antibody (Biolegend, 116502) was used in immunohistochemistry - paraffin section on mouse samples at 1:100 (fig s6l). Nat Commun (2022) ncbi
mouse monoclonal (AF6-88.5)
  • flow cytometry; mouse; 1:40; loading ...; fig 4b, s7c
BioLegend Gm10499 antibody (BioLegend, 116511) was used in flow cytometry on mouse samples at 1:40 (fig 4b, s7c). J Immunother Cancer (2022) ncbi
mouse monoclonal (28-8-6)
  • flow cytometry; mouse; 1:200
BioLegend Gm10499 antibody (BioLegend, 114605) was used in flow cytometry on mouse samples at 1:200. Nat Commun (2021) ncbi
mouse monoclonal (34-1-2S)
  • flow cytometry; mouse; 1:200; fig s5c
BioLegend Gm10499 antibody (BioLegend, 114713) was used in flow cytometry on mouse samples at 1:200 (fig s5c). J Immunother Cancer (2021) ncbi
mouse monoclonal (28-8-6)
  • flow cytometry; mouse; 1:200; fig 5a
BioLegend Gm10499 antibody (Biolegend, 28-8-6) was used in flow cytometry on mouse samples at 1:200 (fig 5a). Nat Commun (2021) ncbi
mouse monoclonal (AF6-88.5)
  • blocking or activating experiments; mouse; fig 2d
  • flow cytometry; mouse; loading ...; fig 2c
BioLegend Gm10499 antibody (BioLegend, AF6-88.5) was used in blocking or activating experiments on mouse samples (fig 2d) and in flow cytometry on mouse samples (fig 2c). J Immunother Cancer (2021) ncbi
mouse monoclonal (KH95)
  • flow cytometry; mouse; loading ...; fig 2c
BioLegend Gm10499 antibody (Biolegend, KH95) was used in flow cytometry on mouse samples (fig 2c). J Immunother Cancer (2021) ncbi
mouse monoclonal (28-8-6)
  • flow cytometry; mouse; fig 6h
BioLegend Gm10499 antibody (Biolegend, 114614) was used in flow cytometry on mouse samples (fig 6h). Sci Rep (2021) ncbi
mouse monoclonal (KH95)
BioLegend Gm10499 antibody (BioLegend, KH95) was used . Nature (2020) ncbi
mouse monoclonal (AF6-88.5)
BioLegend Gm10499 antibody (BioLegend, AF6-88.5) was used . Nature (2020) ncbi
mouse monoclonal (28-8-6)
BioLegend Gm10499 antibody (BioLegend, 28-8-6) was used . Nature (2020) ncbi
mouse monoclonal (34-2-12)
  • flow cytometry; mouse; 1:100; fig e9c
BioLegend Gm10499 antibody (BioLegend, 110608) was used in flow cytometry on mouse samples at 1:100 (fig e9c). Nature (2019) ncbi
mouse monoclonal (SF1-1.1)
  • flow cytometry; mouse; 1:100; fig 5e
BioLegend Gm10499 antibody (BioLegend, 116608) was used in flow cytometry on mouse samples at 1:100 (fig 5e). Nature (2019) ncbi
mouse monoclonal (28-14-8)
  • flow cytometry; mouse; 1:100; fig e9c
BioLegend Gm10499 antibody (BioLegend, 114507) was used in flow cytometry on mouse samples at 1:100 (fig e9c). Nature (2019) ncbi
mouse monoclonal (36-7-5)
  • flow cytometry; mouse; loading ...; fig 3d
BioLegend Gm10499 antibody (BioLegend, 114907) was used in flow cytometry on mouse samples (fig 3d). J Exp Med (2020) ncbi
mouse monoclonal (25-D1.16)
  • flow cytometry; mouse; loading ...; fig 1c
BioLegend Gm10499 antibody (Biolegend, 141604) was used in flow cytometry on mouse samples (fig 1c). Cell (2019) ncbi
mouse monoclonal (28-14-8)
  • flow cytometry; mouse; loading ...; fig 3h
BioLegend Gm10499 antibody (Biolegend, 114507) was used in flow cytometry on mouse samples (fig 3h). Oncoimmunology (2019) ncbi
mouse monoclonal (28-8-6)
  • mass cytometry; mouse; loading ...; fig 3, s2
BioLegend Gm10499 antibody (Biolegend, 114602) was used in mass cytometry on mouse samples (fig 3, s2). Science (2019) ncbi
mouse monoclonal (AF6-88.5)
  • flow cytometry; mouse; fig 4a
BioLegend Gm10499 antibody (BioLegend, AF6-88.5) was used in flow cytometry on mouse samples (fig 4a). J Clin Invest (2019) ncbi
mouse monoclonal (AF6-88.5)
  • flow cytometry; mouse; loading ...
BioLegend Gm10499 antibody (BioLegend, AF6-88.5) was used in flow cytometry on mouse samples . Nature (2019) ncbi
mouse monoclonal (25-D1.16)
  • flow cytometry; mouse; loading ...; fig 1a
BioLegend Gm10499 antibody (BioLegend, 141607) was used in flow cytometry on mouse samples (fig 1a). Immunity (2019) ncbi
mouse monoclonal (AF6-88.5)
  • flow cytometry; mouse; loading ...; fig 1b
BioLegend Gm10499 antibody (BioLegend, AF6-88.5) was used in flow cytometry on mouse samples (fig 1b). J Exp Med (2019) ncbi
mouse monoclonal (KH95)
  • flow cytometry; mouse; loading ...; fig 1b
BioLegend Gm10499 antibody (BioLegend, KH95) was used in flow cytometry on mouse samples (fig 1b). J Exp Med (2019) ncbi
mouse monoclonal (AF6-88.5)
  • flow cytometry; mouse; loading ...; fig 2a
BioLegend Gm10499 antibody (BioLegend, AF6-88.5) was used in flow cytometry on mouse samples (fig 2a). PLoS ONE (2018) ncbi
mouse monoclonal (KH95)
  • flow cytometry; mouse; loading ...; fig 4a
BioLegend Gm10499 antibody (BioLegend, KH95) was used in flow cytometry on mouse samples (fig 4a). JCI Insight (2018) ncbi
mouse monoclonal (AF6-88.5)
  • flow cytometry; mouse; loading ...; fig 4a
BioLegend Gm10499 antibody (BioLegend, AF6-88.5) was used in flow cytometry on mouse samples (fig 4a). JCI Insight (2018) ncbi
mouse monoclonal (25-D1.16)
  • flow cytometry; mouse; 1:200; loading ...; fig 1c
BioLegend Gm10499 antibody (Biolegend, 141605) was used in flow cytometry on mouse samples at 1:200 (fig 1c). elife (2018) ncbi
mouse monoclonal (AF6-88.5)
  • flow cytometry; mouse; loading ...; fig s8a
BioLegend Gm10499 antibody (Biolegend, AF6-88.5) was used in flow cytometry on mouse samples (fig s8a). Science (2018) ncbi
mouse monoclonal (KH95)
  • flow cytometry; mouse; loading ...; fig s1b
BioLegend Gm10499 antibody (Biolegend, KH95) was used in flow cytometry on mouse samples (fig s1b). Cancer Immunol Immunother (2019) ncbi
mouse monoclonal (KH95)
  • flow cytometry; mouse; loading ...; fig s1b
BioLegend Gm10499 antibody (BioLegend, KH95) was used in flow cytometry on mouse samples (fig s1b). J Clin Invest (2019) ncbi
mouse monoclonal (28-14-8)
  • flow cytometry; mouse; loading ...; fig 2d
BioLegend Gm10499 antibody (BioLegend, 28-14-8) was used in flow cytometry on mouse samples (fig 2d). PLoS ONE (2018) ncbi
mouse monoclonal (AF6-88.5)
  • flow cytometry; mouse; loading ...; fig 2d
BioLegend Gm10499 antibody (BioLegend, AF6-88.5) was used in flow cytometry on mouse samples (fig 2d). PLoS ONE (2018) ncbi
mouse monoclonal (34-1-2S)
  • flow cytometry; mouse; 1:200; loading ...; fig s1a
BioLegend Gm10499 antibody (Biolegend, 34-1-2 S) was used in flow cytometry on mouse samples at 1:200 (fig s1a). Oncoimmunology (2018) ncbi
mouse monoclonal (AF6-88.5)
  • flow cytometry; mouse; loading ...; fig s1a
BioLegend Gm10499 antibody (Biolegend, 116507) was used in flow cytometry on mouse samples (fig s1a). Cell (2018) ncbi
mouse monoclonal (28-8-6)
  • immunohistochemistry; mouse; loading ...; fig s3c
In order to evaluate host immune-mediated cell rejection in a retinal transplantation model, BioLegend Gm10499 antibody (Biolegend, 114603) was used in immunohistochemistry on mouse samples (fig s3c). Cell Stem Cell (2017) ncbi
mouse monoclonal (KH95)
  • flow cytometry; mouse; fig 6a
In order to show that parasite-specific CD8 positive T cell-induced fatal vascular breakdown and subsequent neuronal death in an animal model of cerebral malaria, BioLegend Gm10499 antibody (BioLegend, KH95) was used in flow cytometry on mouse samples (fig 6a). PLoS Pathog (2016) ncbi
mouse monoclonal (AF6-88.5)
  • flow cytometry; mouse; fig 6a
In order to show that parasite-specific CD8 positive T cell-induced fatal vascular breakdown and subsequent neuronal death in an animal model of cerebral malaria, BioLegend Gm10499 antibody (BioLegend, AF6-88.5) was used in flow cytometry on mouse samples (fig 6a). PLoS Pathog (2016) ncbi
mouse monoclonal (AF6-88.5)
  • flow cytometry; mouse; fig 6b
In order to assess the effects of a genetically encoded chimeric MyD88/CD40 adjuvant, BioLegend Gm10499 antibody (BioLegend, 116508) was used in flow cytometry on mouse samples (fig 6b). PLoS ONE (2016) ncbi
mouse monoclonal (AF6-88.5)
  • flow cytometry; mouse; fig 2
BioLegend Gm10499 antibody (Biolegend, AF6-88.5) was used in flow cytometry on mouse samples (fig 2). Sci Rep (2016) ncbi
mouse monoclonal (SF1-1.1)
  • flow cytometry; mouse; loading ...; fig 1a
BioLegend Gm10499 antibody (BioLegend, SF 1-1.1) was used in flow cytometry on mouse samples (fig 1a). Cancer Immunol Immunother (2016) ncbi
mouse monoclonal (25-D1.16)
  • flow cytometry; mouse; loading ...; fig 3f
BioLegend Gm10499 antibody (BioLegend, 25-D1.16) was used in flow cytometry on mouse samples (fig 3f). Oncotarget (2016) ncbi
mouse monoclonal (28-8-6)
  • flow cytometry; mouse; fig 2
In order to study the requisite for the function of regulatory T cells known as phosphatase PP2A, BioLegend Gm10499 antibody (Biolegend, 114612) was used in flow cytometry on mouse samples (fig 2). Nat Immunol (2016) ncbi
mouse monoclonal (28-14-8)
  • flow cytometry; mouse; 1:200; fig s1
In order to assess the role of NLRC5 to NK-T-cell crosstalk, BioLegend Gm10499 antibody (BioLegend, 28-14-8) was used in flow cytometry on mouse samples at 1:200 (fig s1). Nat Commun (2016) ncbi
mouse monoclonal (SF1-1.1)
  • flow cytometry; mouse; loading ...; fig 2c
BioLegend Gm10499 antibody (Biolegend, SF1-1.1) was used in flow cytometry on mouse samples (fig 2c). Transpl Immunol (2015) ncbi
mouse monoclonal (25-D1.16)
  • western blot; mouse
BioLegend Gm10499 antibody (Biolegend, 141605) was used in western blot on mouse samples . J Vis Exp (2015) ncbi
mouse monoclonal (28-8-6)
  • flow cytometry; mouse; loading ...; fig 4d
In order to determine if therapeutic antiviral T cells eliminate viral load in the brain of mice persistently infected from birth with lymphocytic choriomeningitis virus without causing blood-brain barrier breakdown or tissue damage, BioLegend Gm10499 antibody (BioLegend, 28-8-6) was used in flow cytometry on mouse samples (fig 4d). J Exp Med (2015) ncbi
mouse monoclonal (36-7-5)
  • flow cytometry; hamsters
  • flow cytometry; mouse
BioLegend Gm10499 antibody (Biolegend, 36-7-5) was used in flow cytometry on hamsters samples and in flow cytometry on mouse samples . Cancer Immunol Immunother (2015) ncbi
mouse monoclonal (SF1-1.1)
  • flow cytometry; human; fig s1
BioLegend Gm10499 antibody (Biolegend, 116616) was used in flow cytometry on human samples (fig s1). Proc Natl Acad Sci U S A (2015) ncbi
mouse monoclonal (KH95)
  • flow cytometry; mouse
BioLegend Gm10499 antibody (BioLegend, KH95) was used in flow cytometry on mouse samples . Blood (2014) ncbi
mouse monoclonal (AF6-88.5)
  • flow cytometry; mouse
In order to study the involvement of signal peptide peptidase in MHC class I presentation, BioLegend Gm10499 antibody (Biolegend, AF6-88.5) was used in flow cytometry on mouse samples . J Immunol (2013) ncbi
Invitrogen
mouse monoclonal (5041.16.1)
  • flow cytometry; human; loading ...; fig 2d
  • flow cytometry; mouse; loading ...; fig 7b
Invitrogen Gm10499 antibody (Invitrogen, MA5-17999) was used in flow cytometry on human samples (fig 2d) and in flow cytometry on mouse samples (fig 7b). Nat Commun (2022) ncbi
mouse monoclonal (AF6-88.5.5.3)
  • flow cytometry; mouse; 1:100; loading ...; fig s1a
Invitrogen Gm10499 antibody (eBioscience, 11-5958-80) was used in flow cytometry on mouse samples at 1:100 (fig s1a). EMBO Mol Med (2022) ncbi
mouse monoclonal (AF6-88.5.5.3)
  • flow cytometry; mouse; 1:100; loading ...; fig s10d
Invitrogen Gm10499 antibody (Thermo Fisher, AF6-88.5.5.3) was used in flow cytometry on mouse samples at 1:100 (fig s10d). Sci Rep (2021) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; mouse; loading ...
  • immunocytochemistry; human; fig s2d
Invitrogen Gm10499 antibody (Thermo-Fisher, MA5-11723) was used in flow cytometry on mouse samples and in immunocytochemistry on human samples (fig s2d). J Exp Clin Cancer Res (2021) ncbi
mouse monoclonal (28-14-8)
  • flow cytometry; mouse; loading ...; fig 4b
Invitrogen Gm10499 antibody (Invitrogen, 28-14-8) was used in flow cytometry on mouse samples (fig 4b). Adv Sci (Weinh) (2020) ncbi
mouse monoclonal (SF1-1.1.1)
  • flow cytometry; mouse; 1:50; loading ...; fig 2c
Invitrogen Gm10499 antibody (eBioscience, 17-5957-82) was used in flow cytometry on mouse samples at 1:50 (fig 2c). Stem Cell Res Ther (2020) ncbi
mouse monoclonal (AF6-88.5.5.3)
  • flow cytometry; mouse; loading ...; fig 2g
Invitrogen Gm10499 antibody (eBioscience, 12-5958-80) was used in flow cytometry on mouse samples (fig 2g). Sci Rep (2019) ncbi
mouse monoclonal (28-14-8)
  • flow cytometry; mouse; loading ...; fig 4a
Invitrogen Gm10499 antibody (eBioscience, 28-14-8) was used in flow cytometry on mouse samples (fig 4a). J Exp Med (2018) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...; fig 1a
Invitrogen Gm10499 antibody (eBioscience, W6/32) was used in flow cytometry on human samples (fig 1a). J Immunol (2018) ncbi
mouse monoclonal (W6/32)
  • blocking or activating experiments; human; loading ...; fig s2b
Invitrogen Gm10499 antibody (eBiosciences, w6/32) was used in blocking or activating experiments on human samples (fig s2b). Nat Med (2018) ncbi
mouse monoclonal (AF6-88.5.5.3)
  • flow cytometry; mouse; loading ...; fig e5c
Invitrogen Gm10499 antibody (eBiosciences, AF6-88.5.5.3) was used in flow cytometry on mouse samples (fig e5c). Nature (2018) ncbi
mouse monoclonal (AF6-88.5.5.3)
  • flow cytometry; mouse; loading ...; fig s2f
Invitrogen Gm10499 antibody (eBioscience, 17-5958) was used in flow cytometry on mouse samples (fig s2f). Nat Med (2018) ncbi
mouse monoclonal (AF6-88.5.5.3)
  • flow cytometry; mouse; loading ...; fig 1f
In order to investigate the involvement of Sec22b in antigen cross-presentation and antitumor immunity, Invitrogen Gm10499 antibody (eBiosciences, 11-5958-80) was used in flow cytometry on mouse samples (fig 1f). J Exp Med (2017) ncbi
mouse monoclonal (34-1-2S)
  • flow cytometry; mouse; loading ...; fig 4c
In order to study intestinal immune responses during acute graft-versus-host disease, Invitrogen Gm10499 antibody (eBiosciences, 34-1-2S) was used in flow cytometry on mouse samples (fig 4c). J Clin Invest (2017) ncbi
mouse monoclonal (SF1-1.1.1)
  • flow cytometry; mouse; 1:50; loading ...; fig 9a
In order to study the immune responses in mice infected with GFP-expressing Rickettsia typhi, Invitrogen Gm10499 antibody (eBioscience, SF1-1.1.1) was used in flow cytometry on mouse samples at 1:50 (fig 9a). Infect Immun (2017) ncbi
mouse monoclonal (SF1-1.1.1)
  • flow cytometry; mouse; loading ...; fig s5
In order to study the role of moesin during the generation of TGF-beta-induced T regulatory cells, Invitrogen Gm10499 antibody (eBioscience, SF1-1.1) was used in flow cytometry on mouse samples (fig s5). J Clin Invest (2017) ncbi
mouse monoclonal (SF1-1.1.1)
  • flow cytometry; mouse; fig 1
In order to study the contribution of extracellular vesicle to maternal microchimerism, Invitrogen Gm10499 antibody (eBioscience, SF1-1.1.1) was used in flow cytometry on mouse samples (fig 1). Proc Natl Acad Sci U S A (2017) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; loading ...; fig s9a
Invitrogen Gm10499 antibody (eBiosciences, W6/32) was used in flow cytometry on human samples (fig s9a). PLoS Pathog (2016) ncbi
mouse monoclonal (SF1-1.1.1)
  • blocking or activating experiments; mouse; loading ...
In order to establish and characterize a mouse model of narcolepsy, Invitrogen Gm10499 antibody (eBioscience, SF1-1.1.1) was used in blocking or activating experiments on mouse samples . Proc Natl Acad Sci U S A (2016) ncbi
mouse monoclonal (SF1-1.1.1)
  • flow cytometry; mouse; 1:200; loading ...; fig 9b
In order to investigate the contribution of neutrophils and macrophages during Rickettsia typhi infection, Invitrogen Gm10499 antibody (eBioscience, SF1-1.1.1) was used in flow cytometry on mouse samples at 1:200 (fig 9b). PLoS Negl Trop Dis (2016) ncbi
mouse monoclonal (W6/32)
  • flow cytometry; human; 1:50; fig s2j
In order to develop and characterize a humanized ossicle xenotransplantation approach, Invitrogen Gm10499 antibody (ebioscience, W6/32) was used in flow cytometry on human samples at 1:50 (fig s2j). Nat Med (2016) ncbi
mouse monoclonal (34-1-2S)
  • flow cytometry; mouse; 1:150; fig s1
In order to assess the role of NLRC5 to NK-T-cell crosstalk, Invitrogen Gm10499 antibody (eBioscience, 34-1-2S) was used in flow cytometry on mouse samples at 1:150 (fig s1). Nat Commun (2016) ncbi
mouse monoclonal (28-14-8)
  • flow cytometry; mouse; 1:250; fig 3
In order to assess the role of NLRC5 to NK-T-cell crosstalk, Invitrogen Gm10499 antibody (eBioscience, 28-14-8) was used in flow cytometry on mouse samples at 1:250 (fig 3). Nat Commun (2016) ncbi
mouse monoclonal (W6/32)
  • immunohistochemistry - paraffin section; human; 1:5000; fig 4
In order to determine if there is an association between inclusion body myositis and hepatitis C virus infection, Invitrogen Gm10499 antibody (Thermo Fisher Scientific, W6/32) was used in immunohistochemistry - paraffin section on human samples at 1:5000 (fig 4). Neurology (2016) ncbi
mouse monoclonal (28-14-8)
  • flow cytometry; mouse; fig 3
Invitrogen Gm10499 antibody (eBioscience, 28-14-8) was used in flow cytometry on mouse samples (fig 3). Carbohydr Polym (2015) ncbi
mouse monoclonal (28-14-8)
  • flow cytometry; mouse
Invitrogen Gm10499 antibody (eBioscience, 28-14-8) was used in flow cytometry on mouse samples . Eur J Immunol (2014) ncbi
mouse monoclonal (28-14-8)
  • flow cytometry; mouse; fig 4
In order to investigate the use of mannosylated synthetic long peptides for vaccination, Invitrogen Gm10499 antibody (eBiosciences, 28-14-8) was used in flow cytometry on mouse samples (fig 4). PLoS ONE (2014) ncbi
mouse monoclonal (SF1-1.1.1)
  • flow cytometry; mouse
Invitrogen Gm10499 antibody (eBioscience, 17-5957-82) was used in flow cytometry on mouse samples . Eur J Immunol (2014) ncbi
mouse monoclonal (SF1-1.1.1)
  • blocking or activating experiments; mouse
Invitrogen Gm10499 antibody (eBioScience, SF1-1.1.1) was used in blocking or activating experiments on mouse samples . PLoS ONE (2014) ncbi
mouse monoclonal (AF6-88.5.5.3)
  • flow cytometry; human
  • immunocytochemistry; human; fig 3
Invitrogen Gm10499 antibody (eBioscience, 11-5958-82) was used in flow cytometry on human samples and in immunocytochemistry on human samples (fig 3). J Immunol (2014) ncbi
mouse monoclonal (SF1-1.1.1)
  • flow cytometry; mouse
Invitrogen Gm10499 antibody (eBioscience, SF1-1.1.1) was used in flow cytometry on mouse samples . J Immunol (2014) ncbi
mouse monoclonal (AF6-88.5.5.3)
  • flow cytometry; mouse
Invitrogen Gm10499 antibody (eBioscience, AF6-88.5.5.3) was used in flow cytometry on mouse samples . J Immunol (2014) ncbi
mouse monoclonal (AF6-88.5.5.3)
  • flow cytometry; mouse
Invitrogen Gm10499 antibody (eBioscience, AF6-88.5.5.3) was used in flow cytometry on mouse samples . Br J Cancer (2014) ncbi
mouse monoclonal (W6/32)
  • western blot; human
In order to report that the human herpesvirus-7 U21 gene product interferes with natural killer cell recognition, Invitrogen Gm10499 antibody (Zymed Laboratories, W6/32) was used in western blot on human samples . PLoS Pathog (2011) ncbi
mouse monoclonal (34-1-2S)
  • flow cytometry; mouse
In order to investigate crosstalk between that osteoclasts and T cells, Invitrogen Gm10499 antibody (eBioscience, 34-1-2S) was used in flow cytometry on mouse samples . J Immunol (2009) ncbi
mouse monoclonal (28-14-8)
  • immunohistochemistry - paraffin section; rat
In order to test if renal stem cells exist in the adult kidney and participate in the acute injury repair, Invitrogen Gm10499 antibody (eBioscience, 12-5999-81) was used in immunohistochemistry - paraffin section on rat samples . J Am Soc Nephrol (2006) ncbi
Abcam
rat monoclonal (ER-HR 52)
  • immunohistochemistry; mouse; 1:100; loading ...; fig 5f
Abcam Gm10499 antibody (Abcam, ab15681) was used in immunohistochemistry on mouse samples at 1:100 (fig 5f). EMBO Mol Med (2022) ncbi
rat monoclonal (ER-HR 52)
  • immunohistochemistry - frozen section; mouse; 1:100; loading ...; fig 4c
Abcam Gm10499 antibody (Abcam, ER-HR 52) was used in immunohistochemistry - frozen section on mouse samples at 1:100 (fig 4c). Mol Neurodegener (2018) ncbi
rat monoclonal (ER-HR 52)
  • immunohistochemistry - frozen section; mouse; fig 5g
Abcam Gm10499 antibody (Abcam, ab15681) was used in immunohistochemistry - frozen section on mouse samples (fig 5g). Sci Rep (2016) ncbi
rat monoclonal (ER-HR 52)
  • immunocytochemistry; mouse; 1:200; loading ...; fig s8e
In order to find that coagulation factor XII modulates immune responses, Abcam Gm10499 antibody (Abcam, ER-HR52) was used in immunocytochemistry on mouse samples at 1:200 (fig s8e). Nat Commun (2016) ncbi
Articles Reviewed
  1. Tran N, Ferreira L, Alvarez Moya B, Buttiglione V, Ferrini B, Zordan P, et al. Continuous sensing of IFNα by hepatic endothelial cells shapes a vascular antimetastatic barrier. elife. 2022;11: pubmed publisher
  2. Regev O, Kizner M, Roncato F, Dadiani M, Saini M, Castro Giner F, et al. ICAM-1 on Breast Cancer Cells Suppresses Lung Metastasis but Is Dispensable for Tumor Growth and Killing by Cytotoxic T Cells. Front Immunol. 2022;13:849701 pubmed publisher
  3. Zhao X, Hu S, Zeng L, Liu X, Song Y, Zhang Y, et al. Irradiation combined with PD-L1-/- and autophagy inhibition enhances the antitumor effect of lung cancer via cGAS-STING-mediated T cell activation. iScience. 2022;25:104690 pubmed publisher
  4. Lei X, Lin H, Wang J, Ou Z, Ruan Y, Sadagopan A, et al. Mitochondrial fission induces immunoescape in solid tumors through decreasing MHC-I surface expression. Nat Commun. 2022;13:3882 pubmed publisher
  5. Paldor M, Levkovitch Siany O, Eidelshtein D, Adar R, Enk C, Marmary Y, et al. Single-cell transcriptomics reveals a senescence-associated IL-6/CCR6 axis driving radiodermatitis. EMBO Mol Med. 2022;14:e15653 pubmed publisher
  6. Laffey K, Stiles R, Ludescher M, Davis T, Khwaja S, Bram R, et al. Early expression of mature αβ TCR in CD4-CD8- T cell progenitors enables MHC to drive development of T-ALL bearing NOTCH mutations. Proc Natl Acad Sci U S A. 2022;119:e2118529119 pubmed publisher
  7. Aiken T, Erbe A, Zebertavage L, Komjathy D, Feils A, Rodriguez M, et al. Mechanism of effective combination radio-immunotherapy against 9464D-GD2, an immunologically cold murine neuroblastoma. J Immunother Cancer. 2022;10: pubmed publisher
  8. Taniguchi H, Caeser R, Chavan S, Zhan Y, Chow A, Manoj P, et al. WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC. Cell Rep. 2022;39:110814 pubmed publisher
  9. Xiong W, Gao X, Zhang T, Jiang B, Hu M, Bu X, et al. USP8 inhibition reshapes an inflamed tumor microenvironment that potentiates the immunotherapy. Nat Commun. 2022;13:1700 pubmed publisher
  10. Zhang Y, Huo F, Cao Q, Jia R, Huang Q, Wang Z, et al. FimH confers mannose-targeting ability to Bacillus Calmette-Guerin for improved immunotherapy in bladder cancer. J Immunother Cancer. 2022;10: pubmed publisher
  11. Zhou Q, Liang J, Yang T, Liu J, Li B, Li Y, et al. Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer. EMBO Mol Med. 2022;14:e14502 pubmed publisher
  12. Stoff M, Ebbecke T, Ciurkiewicz M, Pavasutthipaisit S, Mayer Lambertz S, St xf6 rk T, et al. C-type lectin receptor DCIR contributes to hippocampal injury in acute neurotropic virus infection. Sci Rep. 2021;11:23819 pubmed publisher
  13. Malenica I, Adam J, Corgnac S, Mezquita L, Auclin E, Damei I, et al. Integrin-αV-mediated activation of TGF-β regulates anti-tumour CD8 T cell immunity and response to PD-1 blockade. Nat Commun. 2021;12:5209 pubmed publisher
  14. Wu S, Xiao Y, Wei J, Xu X, Jin X, Hu X, et al. MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer. J Immunother Cancer. 2021;9: pubmed publisher
  15. Amoozgar Z, Kloepper J, Ren J, Tay R, Kazer S, Kiner E, et al. Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas. Nat Commun. 2021;12:2582 pubmed publisher
  16. Sánchez del Campo L, Martí Díaz R, Montenegro M, González Guerrero R, Hernández Caselles T, Martínez Barba E, et al. MITF induces escape from innate immunity in melanoma. J Exp Clin Cancer Res. 2021;40:117 pubmed publisher
  17. Brownlie D, Doughty Shenton D, Yh Soong D, Nixon C, O Carragher N, M Carlin L, et al. Metastasis-associated macrophages constrain antitumor capability of natural killer cells in the metastatic site at least partially by membrane bound transforming growth factor β. J Immunother Cancer. 2021;9: pubmed publisher
  18. Wang Y, Mohseni M, Grauel A, Diez J, Guan W, Liang S, et al. SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms. Sci Rep. 2021;11:1399 pubmed publisher
  19. Bekeschus S, Clemen R, Nießner F, Sagwal S, Freund E, Schmidt A. Medical Gas Plasma Jet Technology Targets Murine Melanoma in an Immunogenic Fashion. Adv Sci (Weinh). 2020;7:1903438 pubmed publisher
  20. Yamamoto K, Venida A, Yano J, Biancur D, Kakiuchi M, Gupta S, et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature. 2020;581:100-105 pubmed publisher
  21. Hou M, Han J, Li G, Kwon M, Jiang J, Emani S, et al. Multipotency of mouse trophoblast stem cells. Stem Cell Res Ther. 2020;11:55 pubmed publisher
  22. Canon J, Rex K, Saiki A, Mohr C, Cooke K, Bagal D, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575:217-223 pubmed publisher
  23. Yan D, Wang J, Sun H, Zamani A, Zhang H, Chen W, et al. TIPE2 specifies the functional polarization of myeloid-derived suppressor cells during tumorigenesis. J Exp Med. 2020;217: pubmed publisher
  24. Dong M, Wang G, Chow R, Ye L, Zhu L, Dai X, et al. Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells. Cell. 2019;178:1189-1204.e23 pubmed publisher
  25. Findlay E, Currie A, Zhang A, Ovciarikova J, Young L, Stevens H, et al. Exposure to the antimicrobial peptide LL-37 produces dendritic cells optimized for immunotherapy. Oncoimmunology. 2019;8:1608106 pubmed publisher
  26. Rosshart S, Herz J, Vassallo B, Hunter A, Wall M, Badger J, et al. Laboratory mice born to wild mice have natural microbiota and model human immune responses. Science. 2019;365: pubmed publisher
  27. Sivaram N, McLaughlin P, Han H, Petrenko O, Jiang Y, Ballou L, et al. Tumor-intrinsic PIK3CA represses tumor immunogenecity in a model of pancreatic cancer. J Clin Invest. 2019;130: pubmed publisher
  28. Di Pilato M, Kim E, Cadilha B, Prüßmann J, Nasrallah M, Seruggia D, et al. Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy. Nature. 2019;570:112-116 pubmed publisher
  29. Knox T, Sahakian E, Banik D, Hadley M, Palmer E, Noonepalle S, et al. Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells. Sci Rep. 2019;9:6136 pubmed publisher
  30. Arora H, Wilcox S, Johnson L, Munro L, Eyford B, Pfeifer C, et al. The ATP-Binding Cassette Gene ABCF1 Functions as an E2 Ubiquitin-Conjugating Enzyme Controlling Macrophage Polarization to Dampen Lethal Septic Shock. Immunity. 2019;50:418-431.e6 pubmed publisher
  31. Bern M, Parikh B, Yang L, Beckman D, Poursine Laurent J, Yokoyama W. Inducible down-regulation of MHC class I results in natural killer cell tolerance. J Exp Med. 2019;216:99-116 pubmed publisher
  32. Magallanes Puebla A, Espinosa Cueto P, López Marín L, Mancilla R. Mycobacterial glycolipid Di-O-acyl trehalose promotes a tolerogenic profile in dendritic cells. PLoS ONE. 2018;13:e0207202 pubmed publisher
  33. Sato Y, Bolzenius J, Eteleeb A, Su X, Maher C, Sehn J, et al. CD4+ T cells induce rejection of urothelial tumors after immune checkpoint blockade. JCI Insight. 2018;3: pubmed publisher
  34. Gejman R, Chang A, Jones H, DiKun K, Hakimi A, Schietinger A, et al. Rejection of immunogenic tumor clones is limited by clonal fraction. elife. 2018;7: pubmed publisher
  35. James K, Cosway E, LUCAS B, White A, Parnell S, Carvalho Gaspar M, et al. Endothelial cells act as gatekeepers for LTβR-dependent thymocyte emigration. J Exp Med. 2018;215:2984-2993 pubmed publisher
  36. Theisen D, Davidson J, Briseño C, Gargaro M, Lauron E, Wang Q, et al. WDFY4 is required for cross-presentation in response to viral and tumor antigens. Science. 2018;362:694-699 pubmed publisher
  37. Umezu D, Okada N, Sakoda Y, Adachi K, Ojima T, Yamaue H, et al. Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment. Cancer Immunol Immunother. 2019;68:201-211 pubmed publisher
  38. Vuckovic S, Minnie S, Smith D, Gartlan K, Watkins T, Markey K, et al. Bone marrow transplantation generates T cell-dependent control of myeloma in mice. J Clin Invest. 2019;129:106-121 pubmed publisher
  39. Walwyn Brown K, Guldevall K, Saeed M, Pende D, Önfelt B, MacDonald A, et al. Human NK Cells Lyse Th2-Polarizing Dendritic Cells via NKp30 and DNAM-1. J Immunol. 2018;201:2028-2041 pubmed publisher
  40. Nardo G, Trolese M, Verderio M, Mariani A, De Paola M, Riva N, et al. Counteracting roles of MHCI and CD8+ T cells in the peripheral and central nervous system of ALS SOD1G93A mice. Mol Neurodegener. 2018;13:42 pubmed publisher
  41. Wilson K, Liu H, Healey G, Vuong V, Ishido S, Herold M, et al. MARCH1-mediated ubiquitination of MHC II impacts the MHC I antigen presentation pathway. PLoS ONE. 2018;13:e0200540 pubmed publisher
  42. Luo N, Formisano L, Gonzalez Ericsson P, Sanchez V, Dean P, Opalenik S, et al. Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2. Oncoimmunology. 2018;7:e1438106 pubmed publisher
  43. Zacharakis N, Chinnasamy H, Black M, Xu H, Lu Y, Zheng Z, et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med. 2018;24:724-730 pubmed publisher
  44. Du X, Wen J, Wang Y, Karmaus P, Khatamian A, Tan H, et al. Hippo/Mst signalling couples metabolic state and immune function of CD8α+ dendritic cells. Nature. 2018;558:141-145 pubmed publisher
  45. Han Y, Liu Q, Hou J, Gu Y, Zhang Y, Chen Z, et al. Tumor-Induced Generation of Splenic Erythroblast-like Ter-Cells Promotes Tumor Progression. Cell. 2018;173:634-648.e12 pubmed publisher
  46. Mathew N, Baumgartner F, Braun L, O Sullivan D, Thomas S, Waterhouse M, et al. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med. 2018;24:282-291 pubmed publisher
  47. Alloatti A, Rookhuizen D, Joannas L, Carpier J, Iborra S, Magalhaes J, et al. Critical role for Sec22b-dependent antigen cross-presentation in antitumor immunity. J Exp Med. 2017;214:2231-2241 pubmed publisher
  48. Bruce D, Stefanski H, Vincent B, Dant T, Reisdorf S, Bommiasamy H, et al. Type 2 innate lymphoid cells treat and prevent acute gastrointestinal graft-versus-host disease. J Clin Invest. 2017;127:1813-1825 pubmed publisher
  49. Hauptmann M, Burkhardt N, Munderloh U, Kuehl S, Richardt U, Krasemann S, et al. GFPuv-Expressing Recombinant Rickettsia typhi: a Useful Tool for the Study of Pathogenesis and CD8+ T Cell Immunology in R. typhi Infection. Infect Immun. 2017;85: pubmed publisher
  50. Ansa Addo E, Zhang Y, Yang Y, Hussey G, Howley B, Salem M, et al. Membrane-organizing protein moesin controls Treg differentiation and antitumor immunity via TGF-β signaling. J Clin Invest. 2017;127:1321-1337 pubmed publisher
  51. Bracamonte Baran W, Florentin J, Zhou Y, Jankowska Gan E, Haynes W, Zhong W, et al. Modification of host dendritic cells by microchimerism-derived extracellular vesicles generates split tolerance. Proc Natl Acad Sci U S A. 2017;114:1099-1104 pubmed publisher
  52. Zhu J, Cifuentes H, Reynolds J, Lamba D. Immunosuppression via Loss of IL2rγ Enhances Long-Term Functional Integration of hESC-Derived Photoreceptors in the Mouse Retina. Cell Stem Cell. 2017;20:374-384.e5 pubmed publisher
  53. Swanson P, Hart G, Russo M, Nayak D, Yazew T, Pena M, et al. CD8+ T Cells Induce Fatal Brainstem Pathology during Cerebral Malaria via Luminal Antigen-Specific Engagement of Brain Vasculature. PLoS Pathog. 2016;12:e1006022 pubmed publisher
  54. Tomic A, Varanasi P, Golemac M, Malic S, Riese P, Borst E, et al. Activation of Innate and Adaptive Immunity by a Recombinant Human Cytomegalovirus Strain Expressing an NKG2D Ligand. PLoS Pathog. 2016;12:e1006015 pubmed publisher
  55. Collinson Pautz M, Slawin K, Levitt J, Spencer D. MyD88/CD40 Genetic Adjuvant Function in Cutaneous Atypical Antigen-Presenting Cells Contributes to DNA Vaccine Immunogenicity. PLoS ONE. 2016;11:e0164547 pubmed publisher
  56. Huang M, Zhang W, Guo J, Wei X, Phiwpan K, Zhang J, et al. Improved Transgenic Mouse Model for Studying HLA Class I Antigen Presentation. Sci Rep. 2016;6:33612 pubmed publisher
  57. Bernard Valnet R, Yshii L, Quériault C, Nguyen X, Arthaud S, Rodrigues M, et al. CD8 T cell-mediated killing of orexinergic neurons induces a narcolepsy-like phenotype in mice. Proc Natl Acad Sci U S A. 2016;113:10956-61 pubmed publisher
  58. Saranchova I, Han J, Huang H, Fenninger F, Choi K, Munro L, et al. Discovery of a Metastatic Immune Escape Mechanism Initiated by the Loss of Expression of the Tumour Biomarker Interleukin-33. Sci Rep. 2016;6:30555 pubmed publisher
  59. Papp S, Moderzynski K, Rauch J, Heine L, Kuehl S, Richardt U, et al. Liver Necrosis and Lethal Systemic Inflammation in a Murine Model of Rickettsia typhi Infection: Role of Neutrophils, Macrophages and NK Cells. PLoS Negl Trop Dis. 2016;10:e0004935 pubmed publisher
  60. Terracina K, Graham L, Payne K, Manjili M, Baek A, Damle S, et al. DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer. Cancer Immunol Immunother. 2016;65:1061-73 pubmed publisher
  61. Wang Y, Hu C, Li J, You X, Gao F. Increased translocation of antigens to endosomes and TLR4 mediated endosomal recruitment of TAP contribute to nicotine augmented cross-presentation. Oncotarget. 2016;7:38451-38466 pubmed publisher
  62. Reinisch A, Thomas D, Corces M, Zhang X, Gratzinger D, Hong W, et al. A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells. Nat Med. 2016;22:812-21 pubmed publisher
  63. Göbel K, Pankratz S, Asaridou C, Herrmann A, Bittner S, Merker M, et al. Blood coagulation factor XII drives adaptive immunity during neuroinflammation via CD87-mediated modulation of dendritic cells. Nat Commun. 2016;7:11626 pubmed publisher
  64. Apostolidis S, Rodríguez Rodríguez N, Suárez Fueyo A, Dioufa N, Ozcan E, Crispín J, et al. Phosphatase PP2A is requisite for the function of regulatory T cells. Nat Immunol. 2016;17:556-64 pubmed publisher
  65. Ludigs K, Jandus C, Utzschneider D, Staehli F, Bessoles S, Dang A, et al. NLRC5 shields T lymphocytes from NK-cell-mediated elimination under inflammatory conditions. Nat Commun. 2016;7:10554 pubmed publisher
  66. Uruha A, Noguchi S, Hayashi Y, Tsuburaya R, Yonekawa T, Nonaka I, et al. Hepatitis C virus infection in inclusion body myositis: A case-control study. Neurology. 2016;86:211-7 pubmed publisher
  67. Li Z, Xu X, Weiss I, Jacobson O, Murphy P. Pre-treatment of allogeneic bone marrow recipients with the CXCR4 antagonist AMD3100 transiently enhances hematopoietic chimerism without promoting donor-specific skin allograft tolerance. Transpl Immunol. 2015;33:125-9 pubmed publisher
  68. Pérez Girón J, Gómez Medina S, Lüdtke A, Munoz Fontela C. Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity. J Vis Exp. 2015;:e52803 pubmed publisher
  69. Herz J, Johnson K, McGavern D. Therapeutic antiviral T cells noncytopathically clear persistently infected microglia after conversion into antigen-presenting cells. J Exp Med. 2015;212:1153-69 pubmed publisher
  70. Stermann A, Huebener N, Seidel D, Fest S, Eschenburg G, Stauder M, et al. Targeting of MYCN by means of DNA vaccination is effective against neuroblastoma in mice. Cancer Immunol Immunother. 2015;64:1215-27 pubmed publisher
  71. Cheah M, Chen J, Sahoo D, Contreras Trujillo H, Volkmer A, Scheeren F, et al. CD14-expressing cancer cells establish the inflammatory and proliferative tumor microenvironment in bladder cancer. Proc Natl Acad Sci U S A. 2015;112:4725-30 pubmed publisher
  72. Sun H, Zhang J, Chen F, Chen X, Zhou Z, Wang H. Activation of RAW264.7 macrophages by the polysaccharide from the roots of Actinidia eriantha and its molecular mechanisms. Carbohydr Polym. 2015;121:388-402 pubmed publisher
  73. Wei H, Nash W, Makrigiannis A, Brown M. Impaired NK-cell education diminishes resistance to murine CMV infection. Eur J Immunol. 2014;44:3273-82 pubmed publisher
  74. Rauen J, Kreer C, Paillard A, van Duikeren S, Benckhuijsen W, Camps M, et al. Enhanced cross-presentation and improved CD8+ T cell responses after mannosylation of synthetic long peptides in mice. PLoS ONE. 2014;9:e103755 pubmed publisher
  75. Larsen J, Dall M, Antvorskov J, Weile C, Engkilde K, Josefsen K, et al. Dietary gluten increases natural killer cell cytotoxicity and cytokine secretion. Eur J Immunol. 2014;44:3056-67 pubmed publisher
  76. Lee Chang C, Bodogai M, Moritoh K, Olkhanud P, Chan A, Croft M, et al. Accumulation of 4-1BBL+ B cells in the elderly induces the generation of granzyme-B+ CD8+ T cells with potential antitumor activity. Blood. 2014;124:1450-9 pubmed publisher
  77. Furugaki K, Cui L, Kunisawa Y, Osada K, Shinkai K, Tanaka M, et al. Intraperitoneal administration of a tumor-associated antigen SART3, CD40L, and GM-CSF gene-loaded polyplex micelle elicits a vaccine effect in mouse tumor models. PLoS ONE. 2014;9:e101854 pubmed publisher
  78. Ramakrishnan R, Tyurin V, Tuyrin V, Veglia F, Condamine T, Amoscato A, et al. Oxidized lipids block antigen cross-presentation by dendritic cells in cancer. J Immunol. 2014;192:2920-31 pubmed publisher
  79. Mercadante A, Perobelli S, Alves A, Gonçalves Silva T, Mello W, Gomes Santos A, et al. Oral combined therapy with probiotics and alloantigen induces B cell-dependent long-lasting specific tolerance. J Immunol. 2014;192:1928-37 pubmed publisher
  80. Gujar S, Clements D, Dielschneider R, Helson E, Marcato P, Lee P. Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms. Br J Cancer. 2014;110:83-93 pubmed publisher
  81. Oliveira C, Querido B, Sluijter M, de Groot A, van der Zee R, Rabelink M, et al. New role of signal peptide peptidase to liberate C-terminal peptides for MHC class I presentation. J Immunol. 2013;191:4020-8 pubmed publisher
  82. Schneider C, Hudson A. The human herpesvirus-7 (HHV-7) U21 immunoevasin subverts NK-mediated cytoxicity through modulation of MICA and MICB. PLoS Pathog. 2011;7:e1002362 pubmed publisher
  83. Kiesel J, Buchwald Z, Aurora R. Cross-presentation by osteoclasts induces FoxP3 in CD8+ T cells. J Immunol. 2009;182:5477-87 pubmed publisher
  84. Gupta S, Verfaillie C, Chmielewski D, Kren S, Eidman K, Connaire J, et al. Isolation and characterization of kidney-derived stem cells. J Am Soc Nephrol. 2006;17:3028-40 pubmed